Cargando…

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rijavec, Erika, Coco, Simona, Genova, Carlo, Rossi, Giovanni, Longo, Luca, Grossi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017364/ https://www.ncbi.nlm.nih.gov/pubmed/31861557 http://dx.doi.org/10.3390/cancers12010017

Ejemplares similares

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019)

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
por: Coco, Simona, et al.
Publicado: (2017)

Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020)

Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch System
por: Truini, Anna, et al.
Publicado: (2014)

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Cusato, Jessica, et al.
Publicado: (2019)

Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review
por: Indini, Alice, et al.
Publicado: (2021)

Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples
por: Bonfiglio, Silvia, et al.
Publicado: (2016)

Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients
por: Puzone, Roberto, et al.
Publicado: (2013)

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I–III Non-Small Cell Lung Cancer
por: Grossi, Francesco, et al.
Publicado: (2015)

Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Genova, Carlo, et al.
Publicado: (2023)

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019)

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
por: Dono, Mariella, et al.
Publicado: (2019)

Novel treatment strategies for early-stage lung cancer: the oncologist’s perspective
por: Indini, Alice, et al.
Publicado: (2020)

Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016)

Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform
por: Vanni, Irene, et al.
Publicado: (2015)

Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
por: Indini, Alice, et al.
Publicado: (2021)

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer
por: Coco, Simona, et al.
Publicado: (2019)

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer
por: Pesta, Martin, et al.
Publicado: (2022)

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives
por: Yang, Ying, et al.
Publicado: (2023)

Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
por: Carbone, Federico, et al.
Publicado: (2021)

Neoadjuvant Chemo-Immunotherapy for Locally Advanced Non-Small-Cell Lung Cancer: A Review of the Literature
por: Franzi, Sara, et al.
Publicado: (2022)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
por: Nacchio, Mariantonia, et al.
Publicado: (2020)

Reply to the Letter to the Editor by C. Nicolazzo et al.: “Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy”
por: Alama, Angela, et al.
Publicado: (2017)

The Prospect and Challenges to the Flow of Liquid Biopsy in Africa
por: Temilola, Dada Oluwaseyi, et al.
Publicado: (2019)

Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?
por: Calabrese, Fiorella, et al.
Publicado: (2019)

Update on liquid biopsy in clinical management of non-small cell lung cancer
por: Wu, Zhen, et al.
Publicado: (2019)

Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy
por: Lu, Jun, et al.
Publicado: (2018)

Future directions and management of liquid biopsy in non-small cell lung cancer
por: Cossu, Alessia Maria, et al.
Publicado: (2020)

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
por: Vicidomini, Giovanni, et al.
Publicado: (2020)

HTA challenges for personalized medicine: the case of liquid biopsy for lung cancer
por: Aguilera-Cobos, L, et al.
Publicado: (2023)

Clinical potential of necitumumab in non-small cell lung carcinoma
por: Genova, Carlo, et al.
Publicado: (2016)

Integrating Liquid Biopsy and Radiomics to Monitor Clonal Heterogeneity of EGFR-Positive Non-Small Cell Lung Cancer
por: Cucchiara, Federico, et al.
Publicado: (2020)

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
por: Crocetto, Felice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o61em26ildo9vaoe14s610tl7a